Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HMGCR | P04035 | 1/20 | 0.42 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9972448 | 0.88 | HDAC8 (0.43) | KMT2AHDAC8HDAC1HTR4MEN1 | |
| SCHEMBL9116393 | 0.88 | HMGCR (0.59) | KMT2ACYP3A4HDAC8HDAC1HMGCR | |
| SCHEMBL9115089 | 0.88 | HMGCR (0.59) | KMT2ACYP3A4HDAC8HDAC1HMGCR | |
| SCHEMBL1441269 | 0.88 | HMGCR (0.59) | KMT2ACYP3A4HDAC8HDAC1HMGCR | |
| SCHEMBL27200200 | 0.88 | CTNNB1 (0.43) | KMT2ACYP3A4HDAC8HDAC1HMGCR | |
| SCHEMBL9117235 | 0.88 | HMGCR (0.59) | KMT2ACYP3A4HDAC8HDAC1HMGCR | |
| SCHEMBL9506703 | 0.86 | HDAC8 (0.42) | KMT2ACYP3A4HDAC8HDAC1HMGCR | |
| SCHEMBL9116037 | 0.86 | HMGCR (0.61) | KMT2ACYP3A4HDAC8HDAC1HMGCR | |
| SCHEMBL8574455 | 0.82 | KMT2A (0.50) | KMT2ACYP3A4HDAC8HDAC1HMGCR | |
| SCHEMBL7267209 | 0.82 | MAPT (0.55) | KMT2AHDAC8HDAC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546402-B2 | Chromone derivatives, a process for their preparation and their therapeutic applications | SOKOLOFF PIERRE (FR) | 2013-10-01 | — | — | US | disclosed |
| US-8546402-B2 | Chromone derivatives, a process for their preparation and their therapeutic applications | SOKOLOFF PIERRE (FR) | 2013-10-01 | — | — | US | disclosed |
| EP-2470520-B1 | CHROMONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS | PF MEDICAMENT (FR) | 2013-07-17 | — | — | EP | disclosed |
| EP-2470520-A1 | CHROMONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS | Pierre Fabre Medicament (FR) | 2012-07-04 | — | — | EP | disclosed |
| US-20120157463-A1 | CHROMONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS | PIERRE FABRE MEDICAMENT (FR) | 2012-06-21 | — | — | US | disclosed |
| US-20120157463-A1 | CHROMONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS | PIERRE FABRE MEDICAMENT (FR) | 2012-06-21 | — | — | US | disclosed |
| WO-2011027289-A1 | CHROMONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS | PIERRE FABRE MEDICAMENT (FR) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011027289-A1 | CHROMONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS | PIERRE FABRE MEDICAMENT (FR) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157463-A1 | CHROMONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS | CHRNA3, CHRM3, VDR | KMT2A 3560/4885CYP3A4 115/4885HDAC8 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.